Skip to main content
OpenTrials
Completed

NCT Number: NCT00985348

Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)

To demonstrate the bioequivalence of a Levetiracetam dry syrup (50% (500mg/1000mg)) versus Levetiracetam 500 mg oral tablet, used as reference, after single dose administration in healthy Japanese subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

London, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent dated and signed by subject.
  • Healthy male or female Japanese volunteer from the first generation, living outside of Japan for less than 10 years, age range 20 to 55 years inclusive.
  • Body Mass Index (BMI) between 18.0 and 28.0 kg/m² inclusive.

Exclusion criteria

  • Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method.
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication.
  • History of drug addiction or presence of drug addiction (positive drug screen) or excessive use of alcohol (weekly intake in excess of 21 units alcohol for male and 14 units alcohol for female; one unit alcohol equals one glass of beer or lager, a glass of wine or a measure of spirits), of psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.
  • Heavy caffeine drinker (drinking >5 cups of coffee or equivalent, approximately 500mg of caffeine per day).
  • Smokers of more than 10 cigarettes per day or smokers not willing to abstain from smoking while in the clinic for each period.

Treatment and study plan

Levetiracetam (Keppra)

Drug

Test Drug :

Levetiracetam dry syrup

Reference Drug :

500 mg oral tablets of Levetiracetam. Frequency: Single Dose

Other names: Keppra

Primary outcomes

  1. Cmax (maximum plasma concentration) of Levetiracetam.

    Time frame: 36 hours

  2. AUC (0-t) (Area under the plasma concentration vs. time curve observed from time 0 h up to the last measurable data point) of Levetiracetam

    Time frame: 36 hours

  3. AUC (Area under the curve extrapolated to infinity) of Levetiracetam

    Time frame: 36 hours

Secondary outcomes

  1. tmax (time of maximum plasma concentration) of Levetiracetam

    Time frame: 36 hours

  2. λz (Terminal elimination rate constant) of Levetiracetam

    Time frame: 36 hours

  3. t1/2 (Terminal elimination half-life) of Levetiracetam

    Time frame: 36 hours

  4. MRT (Mean Residence Time) of Levetiracetam

    Time frame: 36 hours

  5. CL/F (Apparent total body clearance) of Levetiracetam

    Time frame: 36 hours

  6. Vz/F (Apparent volume of distribution) of Levetiracetam

    Time frame: 36 hours

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

Randomized, Monocenter, Open Label, Two-way Cross-over, Single Dose Bioequivalence Study of Two Oral Formulations of Levetiracetam in Healthy Male & Female Japanese Subjects

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Sep 28, 2009
Registry last updated
May 16, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.